Opendata, web and dolomites

PANACHE SIGNED

Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PANACHE" data sheet

The following table provides information about the project.

Coordinator
VRIJE UNIVERSITEIT BRUSSEL 

Organization address
address: PLEINLAAN 2
city: BRUSSEL
postcode: 1050
website: www.vub.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 3˙503˙628 €
 EC max contribution 3˙503˙628 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2018-2019-2020-01
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2024-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) coordinator 1˙718˙150.00
2    UNIVERSITE DE GENEVE CH (GENEVE) participant 1˙032˙266.00
3    FUNDACION PROFESOR NOVOA SANTOS ES (A CORUNA) participant 488˙437.00
4    PROTOQSAR 2000 SL ES (VALENCIA) participant 264˙775.00

Map

 Project objective

The modulation of membrane-bound proteins by drugs is receiving increasing attention from both academia and industry. Among such proteins are pannexin1 (Panx1), connexin43 (Cx43) and connexin32 (Cx32) that form hemichannels at the plasma membrane surface. These hemichannels mediate cellular communication and have emerged as key players in inflammation. This carries translational relevance, as hemichannel inhibition could represent an innovative strategy for the treatment of a plethora of diseases. However, a hurdle in clinical exploration is the lack of appropriate hemichannel inhibitors. PANACHE therefore is a timely project, as it will generate a new type of Panx1, Cx43 and Cx32 hemichannel inhibitors. As proof-of-concept, the generated Panx1, Cx43 and Cx32 hemichannel inhibitors will be tested for their potential to alleviate pathological features in animal models of inflammatory diseases in the cardiovascular system, liver and joints. This will be accomplished by joining academic and industrial scientists from the chemical, chemo-informatics and biomedical fields as well as by relying on in vitro and in silico studies, animal experimentation and testing human material. PANACHE will allow taking a leap forward to the realization of its long-term vision, namely the production of metabolically robust and selective Panx1, Cx43 and Cx32 hemichannel inhibitors that can be used for the establishment of a generic approach to synergize current therapy of hard-to-treat inflammatory diseases. Hence, PANACHE is a foundational project, laying the basis for follow-up initiatives to scrutinize the versatile anti-inflammatory therapeutic actions of the Panx1, Cx43 and Cx32 hemichannel inhibitors.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANACHE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANACHE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

ATEMPGRAD (2019)

Analysing Temperature Effects with a Mobile and Precise Gradient Device

Read More